/MMED

MMED

MMED

$22.50USD↑+0.27%+0.06 today

MARKET CAP

6.3B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$22 – $24

52W RANGE

$11

$24

AI Summary

Stalk

Buy NowMedium

MMED remains entrenched in a medium-term uptrend driven by rising EMAs and positive relative strength, but the recent Bullish Exhaustion pattern and RSI rollover indicate waning upside momentum. Price is currently testing the rising 9-day EMA around the 22.3 zone; holding this level would set up continuation participation, whereas a break beneath the 20-day EMA near 21.25 risks a deeper pullback. Given the structural bullish bias, we recommend a Buy Now posture on an EMA support hold, while monitoring overbought readings and exhaustion risk. A decisive close below the 20-day EMA would invalidate this bullish stance.

↑Q2 revenue $837M (+15.6% YoY) demonstrates strong demand
↑Avg. 12-month PT $21.62 vs. $18.05 spot price (~20% upside)
↓Adj. loss of $0.68/sh missed consensus of -$0.22, signaling cost issues

Full analysis →

Buying

7

institutions

Selling

2

institutions

New Positions

4

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
MM Millennium Management LLC Q2 2026	BUY	3.06 M	45.76 M	+467.18 K	+18.3%	0.02%
CA Citadel Advisors LLC Q2 2026	BUY	2.90 M	43.39 M	+39.86 K	+1.6%	0.00%
BI Blackrock, Inc. Q2 2026	BUY	2.00 M	29.85 M	+1.97 M	+7542.8%	0.00%
RT Renaissance Technologies LLC Q2 2026	BUYNEW	88.30 K	1.32 M	+88.30 K	+0.0%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	SELL	15.39 K	230.16 K	+-1.12 M	-98.7%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	BUYNEW	12.57 K	187.89 K	+12.57 K	+0.0%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUYNEW	11.93 K	177.53 K	+11.93 K	+0.0%	0.00%
RC Rockefeller Capital Management L.P. Q2 2026	BUYNEW	78.00	1.17 K	+78.00	+0.0%	0.00%
BA Balyasny Asset Management L.P. Q2 2026	SELL	0.00	0.00	+-854.75 K	-100.0%	0.00%